LAWRENCE, Mass., May 20, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM) yesterday announced the Company's first annual Zenith Award winners, the critical care nurses in the Cardiovascular Intensive Care Unit (CVICU) at Medical City Dallas Hospital (MCDH). As a leading manufacturer of dialysis products, NxStage created the Zenith Award to recognize critical care nurses who deliver outstanding renal care to patients. NxStage is proud to recognize this group for their ability to improve timeliness of renal therapy for these patients, improve accuracy, and increase staff competency.
The critical care team at MCDH achieved these results by involving physicians in catheter placement to reduce potential renal replacement treatment delays, collaborating with other ICU managers to extend training programs and reduce potential errors, and organized multiple hands-on learning opportunities to increase staff competency with the NxStage System One. Megan Brunson, RN Manager of MCDH's CVICU, submitted a nomination for the award on behalf of her team who proudly accepted it at a NxStage-sponsored educational event during the NTI & Critical Care Exposition in San Diego on May 19, 2015.
"The CVICU bedside staff articulated the need for excellence in the care of the renal patient and championed a multi-disciplinary approach," said Brunson. "As the flagship hospital of the North Texas Division of HCA, Medical City CVICU is honored to accept this award and continue to collaborate with NxStage on the improvement of care in this population of patients."
"NxStage is proud to recognize the accomplishments of critical care nurses for their dedication to patients," said NxStage President, Joe Turk. "NxStage recognizes how stressful the ICU environment is for critical care nurses and so we make it our mission to help simplify the delivery of renal replacement therapy through our technology. We applaud the CVICU at Medical City Dallas, and all of the applicants, for their achievements."
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
Tel: (978) 332-5923
SOURCE NxStage Medical, Inc.